Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burges

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Histochemistry and Cell Biology|May 11, 2020
Sirtuin1 expression and survival in endometrial and clear-cell uterine cancerSusanne Beyer, Fangfang Chen, Sarah Meister, et al.
Archives of Gynecology and Obstetrics|December 6, 2021
The role of resveratrol, Sirtuin1 and RXRα as prognostic markers in ovarian cancerFangfang Chen, Thomas Kolben, Sarah Meister, et al.
Scientific Reports|February 4, 2022
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatinSusann Badmann, Doris Mayr, Elisa Schmoeckel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2019
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU StudyOlivier Colomban, Michel Tod, Alexandra Leary, et al.
Journal of Cancer Research and Clinical Oncology|June 21, 2022
Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancerThomas Kolben, Lena Müller, Sarah Meister, et al.
Cancers|August 29, 2019
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian CancerKatharina Dötzer, Friederike Schlüter, Markus Bo Schoenberg, et al.
British Journal of Clinical Pharmacology|June 3, 2015
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patientsHagen Sjard Bachmann, Werner Meier, Andreas du Bois, et al.
Cells|September 28, 2021
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by RupatadineEileen Deuster, Ivi Hysenaj, Maja Kahaly, et al.
Frontiers in Oncology|October 11, 2021
Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian CancerNicole Elisabeth Topalov, Doris Mayr, Clemens Scherer, et al.
Biomedicines|July 2, 2021
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling PathwayYue Liao, Susann Badmann, Till Kaltofen, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Histochemistry and Cell Biology|May 11, 2020
Sirtuin1 expression and survival in endometrial and clear-cell uterine cancerSusanne Beyer, Fangfang Chen, Sarah Meister, et al.
Archives of Gynecology and Obstetrics|December 6, 2021
The role of resveratrol, Sirtuin1 and RXRα as prognostic markers in ovarian cancerFangfang Chen, Thomas Kolben, Sarah Meister, et al.
Scientific Reports|February 4, 2022
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatinSusann Badmann, Doris Mayr, Elisa Schmoeckel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2019
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU StudyOlivier Colomban, Michel Tod, Alexandra Leary, et al.
Journal of Cancer Research and Clinical Oncology|June 21, 2022
Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancerThomas Kolben, Lena Müller, Sarah Meister, et al.
Cancers|August 29, 2019
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian CancerKatharina Dötzer, Friederike Schlüter, Markus Bo Schoenberg, et al.
British Journal of Clinical Pharmacology|June 3, 2015
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patientsHagen Sjard Bachmann, Werner Meier, Andreas du Bois, et al.
Cells|September 28, 2021
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by RupatadineEileen Deuster, Ivi Hysenaj, Maja Kahaly, et al.
Frontiers in Oncology|October 11, 2021
Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian CancerNicole Elisabeth Topalov, Doris Mayr, Clemens Scherer, et al.
Biomedicines|July 2, 2021
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling PathwayYue Liao, Susann Badmann, Till Kaltofen, et al.
Pageof 12